UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

A phase III study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.TPS266-TPS266

2020

Volltextzugriff (PDF)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer

Journal for immunotherapy of cancer, 2023-06, Vol.11 (6), p.e006658

2023

Volltextzugriff (PDF)

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

The New England journal of medicine, 2020-12, Vol.383 (23), p.2207-2218

2020

Volltextzugriff (PDF)

Therapeutic Advances in Pancreatic Cancer

Gastroenterology (New York, N.Y. 1943), 2013-06, Vol.144 (6), p.1316-1326

2013

Volltextzugriff (PDF)

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

The New England journal of medicine, 2022-02, Vol.386 (5), p.449-462

2022

Volltextzugriff (PDF)

A phase I study of isunakinra, an IL-1 alfa/beta inhibitor, in combination with nivolumab for patients with solid tumors refractory to standard therapies

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14580-e14580

2023

Volltextzugriff (PDF)

Survival with Cemiplimab in Recurrent Cervical Cancer

The New England journal of medicine, 2022-02, Vol.386 (6), p.544-555

2022

Volltextzugriff (PDF)

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

The Lancet (British edition), 2023-07, Vol.402 (10395), p.41-53

2023

Volltextzugriff (PDF)

Impact of gastric cancer treatment pathways on patient outcomes in a community oncology practice setting

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.299-299

2020

Volltextzugriff (PDF)

An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS2677-TPS2677

2021

Volltextzugriff (PDF)

Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4114-4114

2021

Volltextzugriff (PDF)

Cancer Commons’ virtual tumor board program: A patient-centric advisory panel and real-world data registry

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.527-527

2022

Volltextzugriff (PDF)

Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4610-4610

2020

Volltextzugriff (PDF)

Gemcitabine, nab-paclitaxel, cisplatin, and anakinra (AGAP) treatment in patients with localized pancreatic ductal adenocarcinoma (PDAC)

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.449-449

2018

Volltextzugriff (PDF)

HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3528-3528

2023

Volltextzugriff (PDF)

NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.LBA661-LBA661

2023

Volltextzugriff (PDF)

HER2 testing in colorectal cancer: Concordance analysis between breast and gastric scoring algorithms from the MOUNTAINEER trial

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.198-198

2023

Volltextzugriff (PDF)

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer

Cancer discovery, 2024-06, Vol.14 (6), p.982

2024

Volltextzugriff (PDF)

Exploratory biomarker analyses of the single-arm, phase 2 study of regorafenib plus nivolumab in patients (pts) with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC)

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.89-89

2022

Volltextzugriff (PDF)

A pilot, non-randomized evaluation of the safety of anakinra plus FOLFIRINOX in metastatic pancreatic ductal adenocarcinoma patients

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e15750-e15750

2016

Volltextzugriff (PDF)

NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS4661-TPS4661

2020

Volltextzugriff (PDF)

COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC

Future oncology (London, England), 2024-06, p.1-8

2024

Volltextzugriff (PDF)

A meta-analysis of the accuracy of a neuroendocrine tumor mRNA biomarker (NETest) in the blood

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.606-606

2020

Volltextzugriff (PDF)

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors

Investigational new drugs, 2023-06, Vol.41 (3), p.421-430

2023

Volltextzugriff (PDF)

Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3560-3560

2021

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(55)
Dissertationen
(1)

Sprache

Englisch
(56)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Life Sciences & Biomedicine
(23)
Humans
(19)
Cancer Therapies
(8)
Chemotherapy
(8)
Female
(8)
Oncology
(8)
Male
(7)
Middle Aged
(7)
Patients
(7)
Tumors
(7)
Aged
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(6)
Clinical Neurology
(6)
Metastasis
(6)
Neurosciences & Neurology
(6)
Adult
(5)
Aged, 80 And Over
(5)
Dementia
(5)
General & Internal Medicine
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A phase III study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

Therapeutic Advances in Pancreatic Cancer

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

A phase I study of isunakinra, an IL-1 alfa/beta inhibitor, in combination with nivolumab for patients with solid tumors refractory to standard therapies

Survival with Cemiplimab in Recurrent Cervical Cancer

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Impact of gastric cancer treatment pathways on patient outcomes in a community oncology practice setting

An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors

Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs)

Cancer Commons’ virtual tumor board program: A patient-centric advisory panel and real-world data registry

Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs)

Gemcitabine, nab-paclitaxel, cisplatin, and anakinra (AGAP) treatment in patients with localized pancreatic ductal adenocarcinoma (PDAC)

HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS

NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)

HER2 testing in colorectal cancer: Concordance analysis between breast and gastric scoring algorithms from the MOUNTAINEER trial

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer

Exploratory biomarker analyses of the single-arm, phase 2 study of regorafenib plus nivolumab in patients (pts) with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC)

A pilot, non-randomized evaluation of the safety of anakinra plus FOLFIRINOX in metastatic pancreatic ductal adenocarcinoma patients

NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma

COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC

A meta-analysis of the accuracy of a neuroendocrine tumor mRNA biomarker (NETest) in the blood

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors

Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC)

Suchergebnisse filtern